This page shows the latest progressive supranuclear palsy news and features for those working in and with pharma, biotech and healthcare.
enrolment in phase 2 studies of new MS therapy opicinumab and BIIB092 for progressive supranuclear palsy.
The three targets at the centre of the collaboration with Ireland-based Prothena include: tau protein, already a focus in Alzheimer’s research and other conditions like progressive supranuclear palsy (PSP);
drugs. The antibody - called ABBV-8E12 - is being tested in two phase II trials, one in patients with early Alzheimer's and a second in progressive supranuclear palsy (PSP), a rare ... We see potential in ABBV-8E12 and tau-focused approaches to
Treatment being assessed for a progressive neurodegenerative disorder. AbbVie and partner C2N have started clinical trials of an antibody targeting tau proteins that has just been granted orphan drug status by ... The first-in-class therapy - called
IPN007 is being developed in the first instance for progressive supranuclear palsy (PSP), a serious neurodegenerative disorder that progresses much more quickly than Alzheimer's but is also characterised by tau
Drug-development company Mithridion has won orphan status from the US Food and Drug Administration for a potential treatment for brain disease progressive supranuclear palsy. ... The clinical-stage drug-development company Mithridion has won orphan
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for progressive supranuclear palsy.
750. iPerian/ BMS. Acquisition. CNS/ Tauopathies, mAB IPN007 to treat progressive supranuclear palsy (PSP) (preclinical).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...